During Friday’s Afternoon trade, Shares of Splunk Inc (NASDAQ:SPLK), lost -1.85% to $71.01.
Splunk Inc (SPLK) declared the Corvil Add-on for Splunk that streams network data analytics to Splunk® Enterprise. The Corvil Add-on for Splunk allows customers to route valuable network data analytics into Splunk, making it accessible for real-time analysis and data mining over longer timescales. Download the Corvil Add-on for Splunk now.
With the Corvil Add-on for Splunk software, customers will gain deeper insight into their network data. By combining the richest source of business and application insights from the network, together with machine data harvested from the application servers, Corvil customers can see the full picture of end-to-end transactional performance. Corvil customers can track true user experience with Splunk Enterprise and correlate with network and application server events.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The company’s products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users. It offers Splunk Enterprise, a machine data engine with collection, indexing, search, reporting analysis, alerting, monitoring, and data administration capabilities; and Splunk Cloud service.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), declined -0.95% to $134.08, during its Afternoon trading session.
BioMarin Pharmaceutical Inc. (BMRN) declared the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for the treatment of Duchenne Muscular Dystrophy amenable to exon 51 skipping. Validation of the MAA confirms that the submission is complete and starts the EMA’s standard review process. Day 120 questions will be received on 22 October 2015, leading to a potential CHMP opinion in the first half of 2016 and a European Commission Decision by the third quarter of 2016.
Drisapersen is an investigational antisense oligonucleotide drug candidate for the treatment of the largest subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping. Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to about 13% of DMD patients.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
OraSure Technologies, Inc. (NASDAQ:OSUR), during its Friday’s Afternoon trading session decreased -2.48% to $5.50.
OraSure Technologies, Inc. (OSUR) declared its support of various rapid HIV testing initiatives and events taking place this week in recognition of the 20th Anniversary of National HIV Testing Day, held each year on June 27th. These testing initiatives, happening across the country, will assist encourage thousands of people across the U.S. to get tested for HIV with the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody test.
OraSure Technologies, Inc., together with its auxiliaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products comprise OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepITMAX, OMNIgeneGut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems.
Finally, Anthera Pharmaceuticals Inc (NASDAQ:ANTH), decreased -3.53%, to $8.21.
Anthera Pharmaceuticals Inc (ANTH) declared that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is predictable in the second half of 2016.
Results from CHABLIS-SC1, and eventually CHABLIS-SC2, are anticipated to support marketing approval for blisibimod as a treatment for active SLE that is not controlled by current best practice standard-of-care, counting corticosteroids.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
